Everything below concerns Gastric juice protein. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-24. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
=== Maternal contraindications === Medical conditions that do not allow breastfeeding are fairly rare. Infants that are otherwise healthy uniformly benefit from breastfeeding, however, extra precautions should be taken or breastfeeding avoided in circumstances including certain infectious diseases and medical conditions.
In mid-2017, Wenger brought in two signings; Alexandre Lacazette for a fee of £45m, the club's most expensive signing, and Sead Kolašinac on a free transfer from Schalke 04. On 6 August, Wenger won his seventh FA Community Shield as manager as Arsenal beat Chelsea 4–1 on penalties following a 1–1 score at full time. However, in the 2017–18 FA Cup, Arsenal lost to Nottingham Forest in the third round of the FA Cup, and again stood well outside the top four in the Premier League. The club also dealt with player unrest in the form of Sánchez, who voiced his desire to depart, and Wenger sanctioned a transfer to Manchester United in January 2018, whereby Arsenal received Henrikh Mkhitaryan in a swap-deal. Later that month, he signed Pierre-Emerick Aubameyang for a club-record fee of £56 million. However, these additions did not aid Arsenal's performances as a team, and on 20 April, Wenger announced he would step down as Arsenal manager at the end of the 2017–18 season. His final home game was a 5–0 win against Burnley on 6 May, where he received a standing ovation before the game and was gifted the gold mini-replica Premier League trophy he won during the 2003–04 Invincibles season as a departing gift from Arsenal. He officially concluded his tenure with a 1–0 away win against Huddersfield Town. Wenger later revealed that he wanted to stay at the club until the expiration of his contract, but the club thought it better he leave, with the board informing him in January of their decision to end his contract at the end of the season.
In 1976, Yugoslavia organized the European Championship played in Belgrade and Zagreb. The national team participated in eight World Cups and four Euros, won the Olympic football tournament in 1960 at the Summer Games (they also finished second three times and third once), and developed a reputation for skillful and attacking football, leading them to be dubbed "the Brazilians of Europe". Dragan Džajić holds the record for the most national team caps at 85, between 1964 and 1979. The best scorer is Stjepan Bobek with 38 goals, between 1946 and 1956.
Vitamin K2, the main storage form in animals, has several subtypes, which differ in isoprenoid chain length. These vitamin K2 homologues are called menaquinones, and are characterized by the number of isoprenoid residues in their side chains. Menaquinones are abbreviated MK-n, where M stands for menaquinone, the K stands for vitamin K, and the n represents the number of isoprenoid side chain residues. For example, menaquinone-4 (abbreviated MK-4) has four isoprene residues in its side chain. Menaquinone-4 (also known as menatetrenone from its four isoprene residues) is the most common type of vitamin K2 in animal products since MK-4 is normally synthesized from vitamin K1 in certain animal tissues (arterial walls, pancreas, and testes) by replacement of the phytyl tail with an unsaturated geranylgeranyl tail containing four isoprene units, thus yielding menaquinone-4 which is water soluble in nature. This homolog of vitamin K2 may have enzyme functions distinct from those of vitamin K1. MK-7 and other long-chain menaquinones are different from MK-4 in that they are not produced by human tissue. MK-7 may be converted from phylloquinone (K1) in the colon by Escherichia coli bacteria. However, these menaquinones synthesized by bacteria in the gut appear to contribute minimally to overall vitamin K status. MK-4 and MK-7 are both found in the United States in dietary supplements for bone health.
Sources: en.wikipedia.org
4 Cyt c2+ + O2 + 8 H+(inside) → 4 Cyt c3+ + 2 H2O + 4 H+(outside) Although the heme proteins are the most important class of iron-containing proteins, the iron–sulfur proteins are also very important, being involved in electron transfer, which is possible since iron can exist stably in either the +2 or +3 oxidation states. These have one, two, four, or eight iron atoms that are each approximately tetrahedrally coordinated to four sulfur atoms; because of this tetrahedral coordination, they always have high-spin iron. The simplest of such compounds is rubredoxin, which has only one iron atom coordinated to four sulfur atoms from cysteine residues in the surrounding peptide chains. Another important class of iron–sulfur proteins is the ferredoxins, which have multiple iron atoms. Transferrin does not belong to either of these classes. The ability of sea mussels to maintain their grip on rocks in the ocean is facilitated by their use of organometallic iron-based bonds in their protein-rich cuticles. Based on synthetic replicas, the presence of iron in these structures increased elastic modulus 770 times, tensile strength 58 times, and toughness 92 times. The amount of stress required to permanently damage them increased 76 times.
== Response rates == The response rate is the percentage of patients on whom a therapy has some defined effect; for example, the cancer shrinks or disappears after treatment. When used as a clinical endpoint for trials of cancer treatments, this is often called the objective response rate (ORR). The FDA definition of ORR in this context is "the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period." Another criterion is the clinical benefit rate (CBR), "the total number (or percentage) of patients who achieved a complete response, partial response, or had stable disease for 6 months or more". Each trial, for whatever illness or condition, may define what is considered a complete response (CR) or partial response (PR) to the therapy or intervention. Hence the trials report the complete response rate and the overall response rate which includes CR and PR. (See e.g. Response evaluation criteria in solid tumors, and Small-cell carcinoma treatment, and for immunotherapies, Immune-related response criteria.)
Referees, judges, football directors and chairmen were also involved in the scandal, but all defendants deny charges. Olympiakos were the champions of the Greek Super League at the time. 2015 FIFA corruption case 2015 Italian football match-fixing scandal 2016 United Kingdom football sexual abuse scandal 2017 Rangers Tax Fraud Case. The Supreme court ruled that money paid to players, managers and directors between 2001 and 2010 was in the form of tax free loans. This totalled £47m 2018 Football Leaks - Der Spiegel and the European Investigative Collaborations (EIC) network of journalists, begun publishing various articles relateding to various dirty deals relating to various dodgy deals behind Arab oil owned football clubs Manchester City, PSG, and Russian owned Monaco. Super League plans by current European powerhouses. Questionable dealings of football agents, Doping involving Russian and Spanish players. 2023 Brazilian football match-fixing scandal 2025 Turkish football betting scandal Age fraud in association football 2026 Manchester City F.C. financial breaches scandal: the club is found guilty on 114 of 115 charges from the initial leaks.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.